This indicates that the CCL20–CCR6 axis may have two clinically relevant functions: while CCL20 secretion by AML cells might have an anti-tumor effect, the CCR6 receptor could have a pro-tumor effect in AML. The gene discussed is CCL20; the disease is neoplasm.